Received Feb 13, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | UNK | LA |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | LA |
Flu like symptoms; This non-serious case was reported by a consumer via call center representative and described the occurrence of influenza-like symptoms in a 61-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Tdap Vaccine) for prophylaxis. On 05-FEB-2026, the patient received the 2nd dose of Shingrix (left arm) and Tdap Vaccine (left arm). On 05-FEB-2026, less than a day after receiving Shingrix and Tdap Vaccine, the patient experienced influenza-like symptoms (Verbatim: Flu like symptoms). The outcome of the influenza-like symptoms was not resolved. It was unknown if the reporter considered the influenza-like symptoms to be related to Shingrix and Tdap Vaccine. It was unknown if the company considered the influenza-like symptoms to be related to Shingrix and Tdap Vaccine. Additional Information: GSK receipt date: 05-FEB-2026 The received the Shingrix with an unknown Tdap vaccine. The reporter states that she developed flu like symptoms after receiving the vaccine that persist. The batch number was not provided, and we are unable to contact the reporter.